1. Scrip
  2. >>Therapy Areas

How NGM Bio Intends To Build An Old-School Biotech

 
• By Mike Ward

NGM Biopharmaceuticals CEO Jeff Jonker discusses the company's lead program in NASH and its other R&D activities and business strategy in an interview with Scrip's Mike Ward.

Video interview
NGM Bio's Jeff Jonker talks NASH

With the hepatitis C challenge broadly solved, the leading cause of expensive liver transplants is now a disease called non-alcoholic steatohepatitis (NASH), which, not surprisingly, is attracting a lot of attention from companies looking to develop treatments.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.